TABLE 10.

Patient characteristics at baseline and after the 8‐week intake of Symbiota® (MS‐20) or Placebo.

Characteristic a	MS‐20 (n = 50)		Placebo (n = 50)		p value §
	Baseline	Week 8	Baseline	Week 8
Homocysteine, μmol/L	8.8 [7.3, 10.7]	8.3 [6.9, 10.2]	8.9 [7.4, 10.8]	8.2 [7.3, 10.1]	.96
Fasting glucose, mg/dL	90 [84.3, 95.8]	89 [85, 96.8]	89 [86, 93]	88.5 [83.3, 92]	.17
AST, U/L	17 [15, 20]	16.5 [15, 21.8]	16.5 [15, 21]	16 [14, 19]	.05
Creatinine, mg/dL	0.7 [0.6, 0.9]	0.7 [0.6, 0.9]	0.7 [0.6, 0.8]	0.7 [0.6, 0.8]	.40
Cholesterol, mg/dL	198 [176.3, 220.5]	203.5 [174, 225.8]	186.5 [169, 215.8]	183 [168, 214.3]	.99
TG, mg/dL	79 [65.3, 102.3]	81.5 [60.3, 110.5]	85.5 [64.5, 120.3]	75 [63, 122.5]	.46
LDL, mg/dL	119.5 [96, 134.8]	115 [91.3, 135.8]	112.5 [94.3, 142.3]	117.5 [95.3, 135]	.61
HDL, mg/dL	61 [50.3, 71.8]	58 [48.5, 70.8]	54.5 [48, 62]	53 [49, 61]	.87
hs‐CRP b , mg/dL	0.07 [0.04, 0.14]	0.06 [0.03, 0.09]	0.07 [0.04, 0.17]	0.07 [0.04, 0.14]	.04*
RBC, M/μL	4.7 [4.4, 5.3]	4.8 [4.4, 5.2]	4.8 [4.4, 5.3]	4.8 [4.4, 5.2]	.18
Hb, g/dL	13.8 [13, 15]	14 [12.9, 14.9]	13.6 [12.9, 14.4]	13.3 [12.7, 14.4]	.30
HCT, %	41.2 [39.8, 44.5]	42.3 [39.6, 45]	41.5 [39.5, 43.8]	40.4 [38.7, 43.5]	.09
MCV, fL	89.4 [86.4, 91.9]	88.7 [85.9, 91.9]	87.9 [83.2, 90.7]	86.8 [83.4, 90.7]	.66
MCH, pg	29.8 [28.7, 30.5]	29.8 [28.7, 30.5]	29.2 [26.3, 30.2]	29.1 [26.2, 30.1]	.65
MCHC, g/dL	33.1 [32.4, 33.6]	33.1 [32.1, 33.8]	32.7 [31.8, 33.5]	33.1 [31.8, 33.6]	.25
Platelet, K/μL	264 [235.5, 302]	262 [227, 291.8]	243.5 [218.5, 299.8]	240 [215, 293]	.80
RDW‐CV, %	12.7 [12.1, 13.1]	12.6 [12.1, 13.1]	12.8 [12.2, 14.3]	12.7 [12.1, 13.7]	.10
WBC, K/μL	5.4 [4.6, 6.4]	5.4 [4.6, 6.3]	5.5 [4.8, 6.6]	5.9 [4.3, 6.8]	.95

Note: M: 10⁶ cells; K: 10³ cells.

^§ Statistical significance was determined by Wilcoxon rank‐sum test to compare the changes from baseline between groups (*p < .05).

^a All values are expressed as median [Q1, Q3].

^b Only data above the detection limit (0.02 mg/dL) are included into statistics. MS‐20 (n = 46); Placebo (n = 47).